[
  {
    "ts": null,
    "headline": "Columbia Balanced Fund Q1 2025 Commentary",
    "summary": "Columbia Balanced Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=0385c794f7ed58aa50e2427ed31d1d76b351c3bcb93035845a5783a9f42968ef",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748042100,
      "headline": "Columbia Balanced Fund Q1 2025 Commentary",
      "id": 134684612,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=0385c794f7ed58aa50e2427ed31d1d76b351c3bcb93035845a5783a9f42968ef"
    }
  },
  {
    "ts": null,
    "headline": "Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity",
    "summary": "Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity",
    "url": "https://finnhub.io/api/news?id=56eb7dcbb9f55f180df50c5e23719066a0e4c161723b428ef0a391dedaf92d4d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748017055,
      "headline": "Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity",
      "id": 134679108,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=56eb7dcbb9f55f180df50c5e23719066a0e4c161723b428ef0a391dedaf92d4d"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies",
    "summary": "NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.",
    "url": "https://finnhub.io/api/news?id=19510f40f7259b52a1bcb3dce3cbb8c4512c2fe03b6b92f42ddb8440597ef0cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748013180,
      "headline": "3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies",
      "id": 134685679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.",
      "url": "https://finnhub.io/api/news?id=19510f40f7259b52a1bcb3dce3cbb8c4512c2fe03b6b92f42ddb8440597ef0cb"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen",
    "summary": "Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some pricing and margin pressures.",
    "url": "https://finnhub.io/api/news?id=c21574f12c724bc0eb41481975e5bb47abae85e9a21eedf454553e72a6d4f9b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748004120,
      "headline": "The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen",
      "id": 134685680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some pricing and margin pressures.",
      "url": "https://finnhub.io/api/news?id=c21574f12c724bc0eb41481975e5bb47abae85e9a21eedf454553e72a6d4f9b5"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers: Not The Dip I Want To Buy (Rating Downgrade)",
    "summary": "Hims & Hers: Not The Dip I Want To Buy (Rating Downgrade)",
    "url": "https://finnhub.io/api/news?id=1db9e06d9c06f486f2e6f420cd95c5103b1889e4834a3b44c3f9d678e683fea4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748002234,
      "headline": "Hims & Hers: Not The Dip I Want To Buy (Rating Downgrade)",
      "id": 134664052,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1db9e06d9c06f486f2e6f420cd95c5103b1889e4834a3b44c3f9d678e683fea4"
    }
  },
  {
    "ts": null,
    "headline": "Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?",
    "summary": "Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.",
    "url": "https://finnhub.io/api/news?id=6723b8b091a6b77518608ce5f37e5c1eb72d9fc217c1ae3d6a56933a9ad8073b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747993615,
      "headline": "Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?",
      "id": 134660926,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2174377045/image_2174377045.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.",
      "url": "https://finnhub.io/api/news?id=6723b8b091a6b77518608ce5f37e5c1eb72d9fc217c1ae3d6a56933a9ad8073b"
    }
  },
  {
    "ts": null,
    "headline": "Amid compounding crackdown, US patients struggle as weight-loss drug discounts fall short",
    "summary": "After years of easily available,cheap copies of Eli Lilly's and Novo Nordisk's highly effectiveweight-loss drugs, some U.S. patients say they are unwilling topay more and are pursuing alternatives...",
    "url": "https://finnhub.io/api/news?id=a1bac2fe4f938b990aaf290d6732199fd5cf88d5ab368b6c5618a834c9291eca",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747988000,
      "headline": "Amid compounding crackdown, US patients struggle as weight-loss drug discounts fall short",
      "id": 134657895,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "After years of easily available,cheap copies of Eli Lilly's and Novo Nordisk's highly effectiveweight-loss drugs, some U.S. patients say they are unwilling topay more and are pursuing alternatives...",
      "url": "https://finnhub.io/api/news?id=a1bac2fe4f938b990aaf290d6732199fd5cf88d5ab368b6c5618a834c9291eca"
    }
  },
  {
    "ts": null,
    "headline": "Health Rounds: Researchers identify best drugs for severe COVID",
    "summary": "A class of drugs known as Januskinase, or JAK, inhibitors, which work by slowing down theimmune system, should be the first-line therapy for patientshospitalized for COVID-19, researchers reported...",
    "url": "https://finnhub.io/api/news?id=c88f575f9b8e7ab1961f486135735716306a2d4710479c46a9b31e79fa935188",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747983691,
      "headline": "Health Rounds: Researchers identify best drugs for severe COVID",
      "id": 134657462,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "A class of drugs known as Januskinase, or JAK, inhibitors, which work by slowing down theimmune system, should be the first-line therapy for patientshospitalized for COVID-19, researchers reported...",
      "url": "https://finnhub.io/api/news?id=c88f575f9b8e7ab1961f486135735716306a2d4710479c46a9b31e79fa935188"
    }
  },
  {
    "ts": null,
    "headline": "Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.",
    "summary": "Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for drugmakers.",
    "url": "https://finnhub.io/api/news?id=8062ff2e781ade5612d612e1985dfd5895dc3b8c85ea04606e84437d016705bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747983600,
      "headline": "Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.",
      "id": 134658385,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for drugmakers.",
      "url": "https://finnhub.io/api/news?id=8062ff2e781ade5612d612e1985dfd5895dc3b8c85ea04606e84437d016705bb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: to present new data at ASCO",
    "summary": "Eli Lilly has announced that new data on several of its experimental treatments will be presented at the 2025 American Society of Clinical Oncology Annual Meeting on 30 May-3 June in Chicago. The...",
    "url": "https://finnhub.io/api/news?id=0d4be06d92d376f47fb865c060cf405859ddcbf5eac65b354bf34b3ffc60291a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747977025,
      "headline": "Eli Lilly: to present new data at ASCO",
      "id": 134656724,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly has announced that new data on several of its experimental treatments will be presented at the 2025 American Society of Clinical Oncology Annual Meeting on 30 May-3 June in Chicago. The...",
      "url": "https://finnhub.io/api/news?id=0d4be06d92d376f47fb865c060cf405859ddcbf5eac65b354bf34b3ffc60291a"
    }
  },
  {
    "ts": null,
    "headline": "2 Growth Stocks to Own for Decades and 1 to Steer Clear Of",
    "summary": "Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.",
    "url": "https://finnhub.io/api/news?id=7a21417003b05e2197a2da997e75914f305c94717fa81c879735e79c2d994329",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747974816,
      "headline": "2 Growth Stocks to Own for Decades and 1 to Steer Clear Of",
      "id": 134658386,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.",
      "url": "https://finnhub.io/api/news?id=7a21417003b05e2197a2da997e75914f305c94717fa81c879735e79c2d994329"
    }
  },
  {
    "ts": null,
    "headline": "Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs",
    "summary": "The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. Beginning in the second half of 2025, the program targets businesses that do not already cover these drugs because of their high […]",
    "url": "https://finnhub.io/api/news?id=ddf5d3cf5461936ad7f95e21f7c0a367d5cc4dc6012b2889a7da0c1f777d77d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747966260,
      "headline": "Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs",
      "id": 134658387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. Beginning in the second half of 2025, the program targets businesses that do not already cover these drugs because of their high […]",
      "url": "https://finnhub.io/api/news?id=ddf5d3cf5461936ad7f95e21f7c0a367d5cc4dc6012b2889a7da0c1f777d77d5"
    }
  }
]